News

To view our January 2013 Newsletter, please click...
PHILADELPHIA, Dec. 1, 2011 /PRNewswire/ -- LORENZ Life Sciences...
As of 2011, the Faculty of Dentistry at Université Laval, Quebec,...

Newsletter

New! January 2013 Newsletter

July 2012 Newsletter

 Register to receive our SOLABS Newsletter and learn about:

  • New publications
  • Upcoming events
  • Product news
  • Expert advice

Register to be first to know about everything new with SOLABS! 

SOLABS Blog

01
May/13

Audit Trails: Patterns and Part 11 Compliance

Written by Philippe Gaudreau

The requirement for audit trails is not related to the evolution of computerized systems. The possibility to audit multiple sorts of operations has always been a major concern with regulatory authorities. It can be quite demanding to maintain audit trails in a “paper world”. Computerized systems can facilitate the process of auditing operations such as creating raw data in laboratories, approving documents or signing-off on training records.

Read more

01
Mar/13

To never forget where we came from

Written by SOLABS

Monday, January 28th, 2013, 11:26 AM Winnipeg time.

It all started there in 2005 with our first “real” sale of SOLABS QM version 2.5, formerly known as Alibaba… engineers and names…

That morning, employees at this GMP plant woke up to release 2.8 of SOLABS QM. This version is faster with a highly improved backend infrastructure. Since this release our support desk’s red phone has been pretty quiet!

Our series of upgrades for all clients is completed. Everyone is now using our 5th major release, SOLABS QM 2.8.

Read more

   
29
Jan/13

Elements to consider when automating QA processes

Written by Craig Henriksen

Once the time comes for a life sciences organization to automate its QA processes……what should be considered before it begins this initiative?

Identify and prioritize the QA processes that must be automated:

1. CAPA/Change Control;

2. Audit/Complaint/Deviation Report;

3. Etc.

Read more

   
04
Jan/13

Arguments in favor of life science organizations pursuing automation with regard to management of their quality processes

Written by Craig Henriksen

 

Ensuring the production and delivery of high quality products is an ongoing issue in the pharmaceutical and medical device manufacturing settings. In order to comply with scrutiny from regulatory agencies as well as consumer expectations, manufacturers in the life sciences industry have established systematic methods to ensure the quality of their manufacturing processes.  An organizations internal quality management system has evolved from a targeted effort to manage individual processes to a recognized need to implement a ‘holistic’ solution that includes management of controlled documents (SOPs, Test Methods, Specifications, etc……), management of Quality Processes (CAPA, Change Control, Complaints, Deviations, etc…..) and Management of Employee Training Records.  The quandary that many life science organizations face is the decision to maintain these Qa processes in a paper-based system, a partially automated system or to implement a fully automated eQMS.

There are a number of persuasive arguments in favor of life science organizations pursuing automation with regard to management of its quality processes…….

  • Impact of an eQMS on an organization’s ‘Overall Cost of Quality’-

The ‘Overall Cost of Quality’ that a manufacturer faces can be defined as follows:

“The sum of all costs associated with poor quality or product failure, including rework and costs incurred in preventing or resolving quality problems”.

With regard to Life Sciences organizations, we can add diminished brand equity, increased scrutiny from regulatory agencies, the potential for receipt of an FDA warning letter as well as hefty fines.  Most Qa leaders agree that an eQMS system allows organizations to manage their Qa processes with more control and more consistency than they would have using manual, paper-based Qa systems.  An automated system minimizes the intrusion of human error in the organizations Qa processes resulting in an improvement in its operational efficiency.  That added efficiency can be expected to help reduce instances of “poor quality and/or product failure” yielding a positive impact on the organization’s overall cost of quality. 

  • Consistent regulatory compliance-(21 CFR, part 11)

Practically speaking, ‘21 CFR, Part 11’ requires drug makers, medical device manufacturers, biotech companies, biologics developers, CROs, and other FDA-regulated industries to implement controls including audits, system validations, audit trails, electronic signatures, and documentation for software and systems.   In order for the "hard copy" produced from an organization’s internal systems to be considered as the authoritative document, the "hard copy" must be a complete and accurate copy of its electronic source and it must be used exclusively for regulated activities.  The stipulation that the FDA places on submission of “hard copy” documents leaves some level of vagueness and interpretation.  An eQMS solution with integrated e-signature functionality goes a long way towards ensuring that an organization is compliant with the demands of regulatory agencies…..consistently. 

 

 

·         Audit ‘Readiness’ -electronic audit trail.

“One of the ways we can expect the FDA to tighten its oversight of the industry is to increase the frequency of audits at Pharma and med device companies, to make certain that manufacturers’ operations are in compliance with all associated regulatory requirements. Although audits are nothing new to many in the industry, the anticipated uptick in these audits as the agency finds new and more efficient ways to perform them will likely catch many companies off guard. This will include a spike in the number of on-site audits performed with little prior notice and may also extend to include remote audits in which companies will submit data electronically”……Tim Mohn, Lifescienceleader.com

The Qa group in any Life Sciences organization works very hard to protect its employer from being the target of FDA audits…….unfortunately, an audit is sometimes unavoidable.  An eQMS allows an organization to respond to an FDA audit more efficiently and more effectively because it will include an ‘electronic audit trail’ that can be generated in minutes rather than hours (or days).

Ensuring the production and delivery of high quality products is an ongoing issue in the pharmaceutical and medical device manufacturing settings. In order to comply with scrutiny from regulatory agencies as well as consumer expectations, manufacturers in the life sciences industry have established systematic methods to ensure the quality of their manufacturing processes. An organizations internal quality management system has evolved from a targeted effort to manage individual processes to a recognized need to implement a 'holistic' solution that includes management of controlled documents (SOPs, Test Methods, Specifications, etc......), management of Quality Processes (CAPA, Change Control, Complaints, Deviations, etc.....) and Management of Employee Training Records. The quandary that many life science organizations face is the decision to maintain these QA processes in a paper-based system, a partially automated system or to implement a fully automated eQMS.

Read more

   
14
Sep/12

Does enterprise software integration really matter in the life sciences industry?

Written by Philippe Gaudreau

At the moment, I would say "No, it does not".

Recently, we have seen a tremendous focus on the introduction of enterprise software integration within the life sciences industry. By definition, enterprise integration for software systems implies that the selected systems should be capable of interacting and, for example, minimize the need to duplicate data entry . In other words, the software integration should facilitate the exchange of information from one system to the other.

Read more

   

Page 1 of 2

<< Start < Prev 1 > >>